EC Number   |
Application |
Reference |
|---|
   3.1.6.1 | analysis |
cytochemical localization of enzyme in cytoplasmic vesicles as a specific detection method for lysosomes |
681811 |
| 3.1.6.1 | analysis |
development of a time-based mass spectrometric assay to analyze substrate conversion and substrate specificity |
750052 |
| 3.1.6.1 | analysis |
distinction of lysosomes and reservosomes by cytochemical localization of enzyme in epimastigote and trypomastigote |
681811 |
| 3.1.6.1 | analysis |
enzyme hydrolyzes dehydroepiandrosterone 3-sulfate and epiandrosterone 3-sulfate in a urine matrix. Purified arylsulfatase contains only sulfatase activity allowing for the selective hydrolysis of sulfate esters in the presence of glucuronide conjugates. The enzyme can be employed for short three-step chemoenzymatic synthesis of 5alpha-androstane-3beta,17beta-diol 17-glucuronide from epiandrosterone 3-sulfate |
-, 750395 |
| 3.1.6.1 | analysis |
high-throughput screen for mutants expressed in Escherichia coli. The alkaline lysis buffer is 1.0 M Tris-HCl at pH 9.0 plus 0.1 % Tween-20 and 2.0 mM 4-aminobenzamidine, mixed with cell suspension at 8:1 to 12:1 ratio for continuous agitation of mixtures in 96-well plates under room temperature. The enzmye tolerates final 0.1 % Tween-20, and activities in lysates are steady from 3 to 9 h and comparable to sonication treatment but better than freezing-thawing |
749618 |
| 3.1.6.1 | medicine |
a one-time injection of human arylsufatase B into injured mouse spinal cord eliminates immunoreactivity for chondroitin sulfates within five days, and up to 9 weeks after injury. After a moderate spinal cord injury, locomotor recovery assessed by the Basso Mouse Scale in arylsulfatase B treated mice improves, compared to the buffer-treated control group, at 6 weeks after injection. After a severe spinal cord injury, mice injected with equivalent units of arylsulfatase B or bacterial chondroitinase ABC improve similarly and both groups achieve significantly more locomotor recovery than the buffer-treated control mice. Serotonin and tyrosine hydroxylase immunoreactive axons are more extensively present in mouse spinal cords treated with arylsulfatase B and chondroitinase ABC, and the immunoreactive axons penetrate further beyond the injury site than in control mice |
730725 |
| 3.1.6.1 | medicine |
assay for the diagnosis of metachromatic leukodystrophy. Determination of arylsulfatase A activity toward the natural substrate, galactosyl-3-sulfate ceramide or sulfatide, is performed using neat sulfatide without chemical modification. The hydrolyzed sulfatide is monitored upon inclusion of the colorimetric reagent Azure A. Within a clinical context, the method definitely discriminates between healthy subject samples and metachromatic leukodystrophy patient samples |
728954 |
| 3.1.6.1 | medicine |
leukocytes of patients with cerebral palsy show lower enzyme activity as compared to control. Km value for 4-nitrocatechol sulfate in patients' leukocytes is about 0.26 mM, in control 0.21 mM, whereas Vmax value in patients reaches only 58% of healthy control. All investigated patients reveal presence of the most common mutations associated with enzyme pseudodeficiency |
667108 |
| 3.1.6.1 | medicine |
potential benefits of ARSA brain gene therapy in patients with metachromatic leukodystrophy, MLD |
708658 |
| 3.1.6.1 | medicine |
the enzyme can be accepted as the enzyme component of antitumor antibody-enzyme conjugates for target chemotherapy |
-, 135535 |
